Literature DB >> 16899828

Can global initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men?

Knut Stavem1, Leiv Sandvik, Jan Erikssen.   

Abstract

STUDY
OBJECTIVES: To determine if the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 0 (subjects at risk for COPD) provides information about long-term mortality risk. DESIGN, SETTING, AND PARTICIPANTS: From 1972 to 1975, clinical, physiologic, and biochemical parameters including respiratory symptoms, spirometry, and physical fitness were measured in 1,999 healthy men aged 40 to 59 years in an occupational cohort, of whom 1,623 had acceptable spirometry findings. In a proportional hazards model with follow-up until 2000, we assessed all-cause mortality according to GOLD stage 0, I, II, and III compared with "normal" subjects, after adjusting for known risk factors and potential confounders.
RESULTS: After 26 years (range, 25 to 27 years), 615 men (38%) had died. In multivariate proportional hazards models, GOLD stage 0 subjects had a nonsignificantly increased hazard of death (hazard ratio [HR], 1.19; p = 0.21) after adjustment for age, smoking, physical fitness, body mass index, systolic BP, and serum cholesterol. Similarly, subjects in GOLD stage I (HR, 1.30; p = 0.05) and stage II (HR, 1.77; p < 0.0001) had increased all-cause mortality. When expanding GOLD stage 0 to comprise patients with any respiratory symptom in a sensitivity analysis, the HR for all-cause mortality increased (HR, 1.35; p = 0.03).
CONCLUSION: There probably is an excess mortality among GOLD stage 0 subjects compared to symptom-free subjects; however, this should be interpreted cautiously and the results vary with the definition of the GOLD stage 0. Subjects in GOLD stage I or stage II had higher mortality than symptom-free subjects.

Entities:  

Mesh:

Year:  2006        PMID: 16899828     DOI: 10.1378/chest.130.2.318

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Clinical and Genetic Associations of Objectively Identified Interstitial Changes in Smokers.

Authors:  Samuel Y Ash; Rola Harmouche; Rachel K Putman; James C Ross; Alejandro A Diaz; Gary M Hunninghake; Jorge Onieva Onieva; Fernando J Martinez; Augustine M Choi; David A Lynch; Hiroto Hatabu; Ivan O Rosas; Raul San Jose Estepar; George R Washko
Journal:  Chest       Date:  2017-05-12       Impact factor: 9.410

2.  Pooled Cohort Probability Score for Subclinical Airflow Obstruction.

Authors:  Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Byron C Jaeger; Patricia A Cassano; Paulo H Chaves; David Couper; David R Jacobs; Ravi Kalhan; Robert Kaplan; Donald Lloyd-Jones; Anne B Newman; George O'Connor; Jason L Sanders; Benjamin M Smith; Yifei Sun; Jason G Umans; Wendy B White; Sachin Yende; Elizabeth C Oelsner
Journal:  Ann Am Thorac Soc       Date:  2022-08

3.  Patterns of healthcare utilization by COPD severity: a pilot study.

Authors:  Min J Joo; Todd A Lee; Brian Bartle; William B van de Graaff; Kevin B Weiss
Journal:  Lung       Date:  2008-05-08       Impact factor: 2.584

4.  Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk.

Authors:  S Guerra; D L Sherrill; C Venker; C M Ceccato; M Halonen; F D Martinez
Journal:  Thorax       Date:  2009-07-05       Impact factor: 9.139

Review 5.  Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.

Authors:  Kokuvi Atsou; Christos Chouaid; Gilles Hejblum
Journal:  BMC Med       Date:  2011-01-18       Impact factor: 8.775

6.  The boundaries of mild chronic obstructive pulmonary disease (COPD): design of the searching clinical COPD onset (SOON) study.

Authors:  Gonzalo Labarca; Andrea Bustamante; Gonzalo Valdivia; Rodrigo Díaz; Álvaro Huete; Paul Mac Nab; Laura Mendoza; Jaime Leppe; Carmen Lisboa; Fernando Saldías; Orlando Díaz
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

7.  Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study.

Authors:  Filip Mejza; Louisa Gnatiuc; A Sonia Buist; William M Vollmer; Bernd Lamprecht; Daniel O Obaseki; Pawel Nastalek; Ewa Nizankowska-Mogilnicka; Peter G J Burney
Journal:  Eur Respir J       Date:  2017-11-22       Impact factor: 16.671

8.  Association Between Non-obstructive Chronic Bronchitis and Incident Chronic Obstructive Pulmonary Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis.

Authors:  Fan Wu; Huanhuan Fan; Jing Liu; Haiqing Li; Weifeng Zeng; Silan Zheng; Heshen Tian; Zhishan Deng; Youlan Zheng; Ningning Zhao; Guoping Hu; Yumin Zhou; Pixin Ran
Journal:  Front Med (Lausanne)       Date:  2022-01-25

9.  Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.

Authors:  Helen Ilumets; Paula Rytilä; Ingel Demedts; Guy G Brusselle; Anssi Sovijärvi; Marjukka Myllärniemi; Timo Sorsa; Vuokko L Kinnula
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  From GOLD 0 to Pre-COPD.

Authors:  MeiLan K Han; Alvar Agusti; Bartolome R Celli; Gerard J Criner; David M G Halpin; Nicolas Roche; Alberto Papi; Robert A Stockley; Jadwiga Wedzicha; Claus F Vogelmeier
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.